Merck Provides Topline Results From Phase 3 KEYNOTE-585 Trial In Locally Advanced Resectable Gastric And Gastroesophageal Junction Adenocarcinoma
Portfolio Pulse from Benzinga Newsdesk
Merck has released topline results from its Phase 3 KEYNOTE-585 trial for locally advanced resectable gastric and gastroesophageal junction adenocarcinoma. The trial did not meet its primary endpoint of improving disease-free survival.
June 20, 2023 | 10:49 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Merck's KEYNOTE-585 trial did not meet its primary endpoint, which may negatively impact the company's stock price.
The failure of the KEYNOTE-585 trial to meet its primary endpoint may lead to a negative perception of Merck's product pipeline and could result in a short-term decline in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100